MARIO PETRINI Ematologia PISA UO Ematologia - Pisa
|
|
- Amber Carter
- 5 years ago
- Views:
Transcription
1 I LINFOMI NON HODGKIN A BASSO GRADO DI MALIGNITA PESCARA 2008 linfomi mantellari MARIO PETRINI Ematologia PISA
2 Mantle Cell Lymphoma Typical (Classic) small to medium-sized Ly with scanty cytoplasm, irregular nuclei, condensed chromatin. Rarely round nuclei (mimicking CLL), or abundant pale cytoplasm (mimicking Marginal Zone Lymphoma) Cytology Blastoid (Blastic) Classic Blastoid Variant: medium-sized Ly with scanty cytoplasm and round nuclei with finely dispersed chromatin and high mitotic index Pleomorphic Blastoid Variant: heterogeneous large cells with irregular cleaved nuclei, finely dispersed chromatin, small distinct nucleoli
3 Mantle Cell Lymphoma - Morphology 3-26% 28-78% 13-39% Architectural Patterns in nodes
4 Mantle Cell Lymphoma - Immunophenotype Monoclonal B cell expressing CD19+ CD20+ CD22+ CD79a+ intense surface immunoglobulin IgM (± IgD) more λ light chain than κ light chain CD5+ (11% -) -CD 10 CD43+ -CD 23 -BCL 6
5 Mantle Cell Lymphoma / CD5 negative Positive t(11;14) by fluorescence in situ hybridization from a CD5- mantle cell lymphoma. Note 1 green, 1 red, and 2 orange fusion signals. The fusion signals indicate the presence of the t(11;14) translocation.
6 Mantle Cell Lymphoma Molecular Biology CDK (Cyclin Dependent Kinase) Cell cycle POSITIVE regulators Cyclin D1 CDK4 Retinoblastoma Protein Phosphorilation Cyclin/CDK complex Release of Transcription factor E2F Cell-cycle progression in S phase
7 Rosenwald et al. Cancer Cell. 2003;3:
8 Rosenwald et al. Cancer Cell. 2003;3: KI-67 results are parallel Other prognostics: Stage, IPI, blastoid morphol.
9 MCL - PFS according to RAF1 expression
10 MCL - PFS according to MYC expression
11 MCL - PFS according to RAF1 expression 19 pz con MCL
12 MCL - PFS according to RAF1 expression Leuk Res. 2007;31:
13 A New Prognostic Index (MIPI) for Patients with AdvancedStage Mantle Cell Lymphoma IPI FLIPI MIPI (età, EGOG, LDH, GB) MIPI b ( + Ki 67%) Based on data of 455 patients with advanced stage MCL from three randomized trials Hoster E, GLSG & European MCL Network.Blood First Edition Paper, prepublished online October 25, 2007
14 INITIAL OBSERVATION WITHOUT THERAPY IN PATIENTS WITH ASYMPTOMATIC, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA (MCL) P. Martin1 Lugano 2008
15 Mantle Cell Lymphoma Treatment: Conventional Chemotherapy G. Lenz, M. Dreyling, W. Hiddemann Ann Hematol 2004
16 Mantle Cell Lymphoma Treatment: Rituximab Romaguera et al, Blood, 2001: R-Hyper-CVAD in 75 MCL pts < 66 years > 66 years R-Hyper-CVAD Hyper-CVAD +ABMT R-Hyper-CVAD Hyper-CVAD +ABMT CR 89% 100% 90% 70% 2-year FFS 84% 75% 60% 41% 2-year OS 87% 96% 96% 77%
17 German Low Grade Lymphoma Study Group: R-CHOP significantly improves response and time to treatment failure but not long-term outcome in untreated MCL Time to treatment failure Overall survival P=.0131 Lenz, G. et al. J Clin Oncol; 23: Copyright American Society of Clinical Oncology
18 Mantle Cell Lymphoma Treatment: SCT
19 Mantle Cell Lymphoma Treatment: SCT 79% 89% 18% 42%
20 Mantle Cell Lymphoma Treatment: SCT
21 MCL - PFS according to FCGR3A genotype
22 MCL - PFS according to FCGR2A genotype
23 Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) Forstpointner et Al BLOOD, 2006; 108: 4003
24 Zevalin in MCL: PFS RIT induction RIT consolidation Weigert O, Jurczak W et al. Proc Am Soc Clin Oncol 2006; 24: #7533
25 Zevalin in MCL: OS RIT induction RIT consolidation Weigert O, Jurczak W et al. Proc Am Soc Clin Oncol 2006; 24: #7533
26 E1499 Trial: R-CHOP followed by Zevalin Consolidation in 1st line MCL Phase II Study 56 Pts. eligible for treatment ORR CR/Cru 50 Pts. evaluable post R-CHOP ORR 72% (CR/CRu 14%, PR 58%); SD 26% 44 Pts. evaluable post Zevalin ORR 84% (CR 45%) Responses improved in 15/ 37 Pts. with < CR/CRu Responders (%) Conclusion Zevalin consolidation improves the number and quality of responses 0 After R-CHOP induction (n=50) After Zevalin consolidation (n=44) Smith MR et al. Proc Am Soc Clin Oncol 2006; 24: # 7503
27 Comparison of 3 Trials assessing RIT consolidation in MCL 1st and 2nd line Jurczak W. et al., Blood 2006;108:#2747
28 Z-BEAM Consolidating Remission OS by disease histology (N=41) PFS by disease histology Krishnan et al J Clin Oncol 2008;28:90 5
29 Radioimmunotherapy as an Alternative Consolidation for Mantle Cell Lymphoma (MCL) patients not Eligible for Transplant Protocols Final Analysis of Multicentre PLRG Trial with 90Y-Zevalin (90Y-ibritumomab tiuxetan) W Jurczak1, et AL Lugano 2008
30 PHASE I TRIAL OF BORTEZOMIB IN COMBINATION WITH RITUXIMABHYPERCVAD/ METHOTREXATE AND CYTARABINE FOR UNTREATEDMANTLE CELL LYMPHOMA. J. E. Romaguera et Al Lugano 2008 Bortezomib can be safely combined with R-M/A at 0.7 mg/m2, toxicity similar to prior experience with R-HyperCVAD. Accrual is ongoing. (7 Pt) BORTEZOMIB IN ASSOCIATION WITH FCM-R AS SALVAGE TREATMEN FOR PATIENTS WITH NON HODGKIN LYMPHOMA F. Zaja Lugano 2008 The results of this pilot study indicate that FCM- BR can be administered without major toxicity and with good activity in the majority of cases.
31 R-CHOP + THALIDOMIDE FOR PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA J. Drach et Al. Lugano 2008 All 10 pts experienced a response to R-CHOP-Thal (with 8 patients in CR; 4 pts were also negative by FDG-PET). DURABLE RESPONSES WITH THE ANTI-ANGIOGENIC METRONOMIC REGIMEN RT-PEPC IN RECURRENT MANTLE CELL LYMPHOMA (MCL) J. Ruan et Al. Lugano 2008 RT-PEPC has significant and durable clinical activity in MCL by targeting both tumor cells and tumor angiogenesis. LENALIDOMIDE IN COMBINATION WITH RITUXIMAB IS EFFECTIVE WITHMANAGEABLE TOXICITY IN A PHASE I/II STUDY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA M. Wang The MTD for Len+R in relapsed/refractory MCL was 20 mg (days 1 21 of a 28-day cycle). Early evidence of response is promising with a favorable toxicity profile at 20 mg.
32 EUROPEAN MANTLE CELL LYMPHOMA NETWORK: AN UPDATE ON CURRENT FIRST LINE TRIALS M. Dreyling et Al Lugano 2008 In MCL elderly, 302 patients are initially randomized between 8 cycles of R-CHOP or 6 cycles of R-FC (experimental arm). Patients who achieve either a PR or CR, receive subsequently either interferon maintenance (standard arm) or a single rituximab dose every 2 months. In MCL younger, 314 patients the standard arm (R-CHOP induction followed by myeloablative consolidation: 12 Gray TBI, 2x 60mg/kg cyclophosphamide) is compared to the implementation of high dose cytarabine into induction (R-CHOP/R-DHAP) and consolidation (10 Gray TBI, 4x1,5 g/m2 Ara-C, 140mg/m2 melphalan).
33 BENDAMUSTINE PLUS RITUXIMAB VERSUS CHOP PLUS RITUXIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH INDOLENT AND MANTLE CELL LYMPHOMAS INTERIM RESULTS OF A RANDOMIZED PHASE IIISTUDY OF THE STIL (STUDY GROUP INDOLENT LYMPHOMAS, GERMANY) M. J. Rummel In this interim analysis the combination of Bendamustine plus Rituximab appears to be non-inferior to CHOP-R while showing a better tolerability profile
34 Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma Thomas E. Witzig Et Al JCO 2005
35 Phase 3 study of patients with relapsed. Refractory MCL: comparison of treatment with Temsirolimus vs investigator s choice therapy. Verhoef E.G, et Al. EHA pt 2-7 previous lines Pt treated with 175/75 mg showed longher PFS Pt treated with 175/25 mg did not significantly differ from controls. No significant improving of OS Adverese events: Thrombocytemia, anemia, neutropenia, asthenia
36 Distinct functional significance of Akt and mtor constitutive activation in mantle cell lymphoma J Dal Col et Al. Blood 2008 To assess whether the PI3-K/Akt and/or mtor signalings regulate MCL cell survival, we investigated the effects of wortmannin, SH-5 (Akt inhibitor), and rapamycin in Granta 519 and SP-53 cells.
37 Day Fludarabine 25 mg/m 2 Bortezomib 1.3 mg/m 2 Myocet 50 mg/m 2 Mabthera (cycle 2 only) 375 mg/m 2
38 Pazienti 21 Pretrattati 18 Fragili 5 Age, years median 66 range Sex Male 14 Female 7 Stage IV 15 IV ext 4 IV int 2 IPI median 3 range 2-4 No. previous CT median 3 range 0-4 ABMT yes 2 no 19 Disease status front line 5 resistant 5 relapsed 11
39 Patient No. Age at diagnoses Sex Stage IPI No. previous CT ABMT Resistant/relapsed M IV int 3 1 no relapse F IV 2 1 no relapse F IV 2 3 no resistant M IV 3 4 no resistant F IV int 3 3 no resistant F IV M IV 3 2 no resistant M IV M IV ext 3 1 no relapse F IV 2 3 no relapse M IV ext 3 3 no relapse M IV ext M IV 3 3 no relapse M IV M IV M IV 3 4 yes relapse F IV ext 3 4 no relapse M IV 3 3 no relapse F IV 3 1 no resistant M IV 2 2 no relapse M IV 3 4 yes relapse
40 ORR 57% % 14.3% 14.3% 9.5% 9.5% CR/uCR PR SD PD Mortality
41 neutropenia piastrinopenia anemia cardiotoxicity nausea diarrhea vomiting coutaneous rash FUO pneumonia death
42 Pazienti Radioimmunoterapia Pz Risposta Biol mol RIT Risposta Biol mol #1 RC JH+ BCL1- Zevalin RC JH- BCL1- #2 RP JH+ BCL1- Zevalin RP JH+ BCL1- #3 RC JH- BCL1- Zevalin RC JH- BCL1- #4 RC JH- BCL1- Zevalin RC JH- BCL1- #5 RC JH- BCL1- Zevalin RC JH- BCL1- #6 RP JH- BCL1- Zevalin RP JH- BCL1- #7 RC JH- BCL1- Zevalin RC In corso #8 RC JH- BCL1- Zevalin RC In corso
43 Pazienti Follow-up Pz EFS Biol mol Evento OS post RIT #1 7 mesi JH+ BCL1+ relapse 12 mesi #2 12 mesi JH+ BCL1- Ancora in RC 12 mesi #3 11 mesi JH- BCL1- Ancora in RC 11 mesi #4 8 mesi JH- BCL1- Ancora in RC 8 mesi #5 6 mesi JH- BCL1- Ancora in RC 6 mesi #6 6 mesi JH- BCL1- Ancora in RC 6 mesi
Mantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationCurrent and Emerging Therapies in Mantle Cell Lymphoma
Current Treatment Options in Oncology (2013) 14:198 211 DOI 10.1007/s11864-013-0230-z Lymphoma (LI Gordon, Section Editor) Current and Emerging Therapies in Mantle Cell Lymphoma L. Kyle Brett, MD Michael
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationMCL comprises less than 10% of all cases of non-hodgkin
COHEN, ZAIN, AND KAHL Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies Jonathon B. Cohen, MD, Jasmine M. Zain, MD, and Brad S. Kahl, MD OVERVIEW Mantle cell lymphoma (MCL)
More informationLondon Cancer New Drugs Group APC/DTC Briefing
London Cancer New Drugs Group APC/DTC Briefing Rituximab for Mantle Cell Lymphoma g Contents Summary Summary & Background 1-2 Introduction 3 Discussion points/issues for Consideration 9 References 12 Background
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationUpdates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics
Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Version 2.2015, 03/03/15 National Comprehensive Cancer Network, Inc. 2015, All
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationLinfoma mantellare: terapia del paziente anziano. Francesco Zaja Trieste
Linfoma mantellare: terapia del paziente anziano Francesco Zaja Trieste Dramatic demographic changes Increasing proportion of elderly persons In 2015 19% of the population in the European Union were 65
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationMantle cell lymphoma-management in evolution
Review Article Page 1 of 8 Mantle cell lymphoma-management in evolution Saurabh Rajguru, Brad S. Kahl Department of Medicine, Division of Hematology/Oncology, University of Wisconsin School of Medicine
More informationOptions in Mantle Cell Lymphoma Therapy
Options in Mantle Cell Lymphoma Therapy Carlo Visco, MD Dept of Cell Therapy and Hematology San Bortolo Hospital, Vicenza, taly My Disclosures: ADVSOR OR ADVSORY BOARDS: Lundbeck Canada nc, Celgene Europe,
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationPanel Discussion/References
Follicular Lymphoma (FOLL) FOLL-B category designation for first-line therapy options for FL: Bendamustine + rituximab RCHOP RCVP Submission from Genentech to review the data related to obinutuzumab for
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationNovita da EHA 2016 Copenhagen Linfomi
Firenze, 16th September 2016 Marco Ladetto MD, Az Osp Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy EU Novita da EHA 2016 Copenhagen Linfomi THREE QUESTIONS TO ADDRESS: 1. Is ASCT still the
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationMantle cell lymphoma: The promise of new treatment options
Critical Reviews in Oncology/Hematology 80 (2011) 69 86 Mantle cell lymphoma: The promise of new treatment options Andre Goy a,, Brad Kahl b a Lymphoma Division, John Theurer Cancer Center, Hackensack
More informationNuove opportunità di cura. Stefano Sacchi, Modena
Nuove opportunità di cura Stefano Sacchi, Modena Antiangiogenesis therapies The goal is to target the blood supply that feeds tumors. Vorinostat (suberoylanilide hydroxamic acid - SAHA) TOPIC SEARCH:
More informationManejo del linfoma de células del manto en la era de las terapias diana
Manejo del linfoma de células del manto en la era de las terapias diana Management of mantle cell lymphoma in the era of targeted drugs LINFOMA DE CÉLULAS DEL MANTO Robak T Department of Hematology, Medical
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Rituximab (MabThera ) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL) DSD: Horizon Scanning in Oncology No.79 ISSN online 2076-5940 Horizon
More informationExpanding the Horizons )N 3UPPORTIVE #ARE /NCOLOGY. Communiqué from ICML 2008
C A n a d i a n V i s i o n f o r O n c o l o g y )N 3UPPORTIVE #ARE /NCOLOGY Number 10 July 2008 PUBLICATIONS MAIL AGREEMENT NO. 41495516 RETURN UNDELIVERABLE CANADIAN ADDRESSES TO NEW EVIDENCE 4133 DUNDAS
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationLymphomas in Prof Paul Ruff Division of Medical Oncology
Lymphomas in 2010 Prof Paul Ruff Division of Medical Oncology Most Common Lymphomas: ~90% B-cell and ~10% T-cell T lymphoblastic: 2% Marginal zone, nodal: 2% Other: 9% Burkitt: 2% Anaplastic large cell:
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationCurrent treatment standards and emerging strategies in mantle cell lymphoma
NON-HODGKIN LYMPHOMA Current treatment standards and emerging strategies in mantle cell lymphoma Martin Dreyling 1 and Wolfgang Hiddemann 1 for the European MCL Network 1 University Hospital Grosshadern,
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationAngioimmunoblastic T-cell lymphoma: nobody knows what to do...
Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Felicitas Hitz, Onkologie/Hämatologie St.Gallen SAMO Lucerne 17.9.2011 : Problems PTCL are rare diseases with even rarer subgroups Difficulte
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationConfronto Real world e studi registrativi
Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY
More informationFrontline Treatment for Older Patients with Mantle Cell Lymphoma
Hematologic Malignancies Frontline Treatment for Older Patients with Mantle Cell Lymphoma HAIGE YE, a,b, AAKASH DESAI, b,c, DONGFENG ZENG, b JORGE ROMAGUERA, b MICHAEL L. WANG b a Department of Hematology,
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationNovel treatment options for Waldenstrom Macroglobulinemia
Novel treatment options for Waldenstrom Macroglobulinemia Irene Ghobrial, MD Associate Professor of Medicine Harvard Medical School Dana Farber Cancer Institute Boston, MA Ghobrial et al, Lancet Oncol
More informationHannover-Meeting Niedrig-malignes NHL. Prof. C. Buske Medizinische Klinik III Klinikum Großhadern LMU München
Hannover-Meeting 2009 Niedrig-malignes NHL Prof. C. Buske Medizinische Klinik III Klinikum Großhadern LMU München Follikuläres Lymphom Konzepte Wenn wir behanden müssen was sollen wir initial dem Patienten
More informationBendamustine and rituximab for the treatment of relapsed indolent and mantle cell lymphoma: when timing of a study matters
Commentary Bendamustine and rituximab for the treatment of relapsed indolent and mantle cell lymphoma: when timing of a study matters Lorenzo Falchi 1, Rita Morales 1, Marco Ruella 2,3,4 1 Division of
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationPOST ICML Indolent lymphomas relapse treatment
POST ICML Indolent lymphomas relapse treatment Georg Hess University Medical School Johannes Gutenberg-University Mainz, Germany Treatment of relapsed indolent lymphoma 2 General categories of second line
More informationB Cell Lymphoma: Aggressive
B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant
More informationNCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
More informationPanel Discussion/References
Follicular Lymphoma (FOLL) Panel discussion to reassess the category designation for lenalidomide + rituximab as a firstline therapy for FL. Panel discussion to reassess the inclusion of radioimmunotherapy
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationTreatment Nodal Marginal Zone Lymphoma
Workshop : Indolent lymphomas Treatment Nodal Marginal Zone Lymphoma Catherine Thieblemont Hôpital Saint-Louis, Paris - France Bologna 16th, 2017 Ø No standardized treatment Ø Similarly treated as FL Treatment
More informationMarked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.
Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Abrahamsson, Anna; Dahle, Nina; Jerkeman, Mats Published in: Leukemia & lymphoma
More informationMANTLE CELL LYMPHOMA MTOR-INHIBITION
MANTLE CELL LYMPHOMA MTOR-INHIBITION Rome, 23. March 2017 Prof. Dr. med. Georg Heß III. Med. Klinik Universitäres Centrum für Tumorerkrankungen Universitätsmedizin der Johannes Gutenberg-Universität Mainz
More informationProgram curriculum developed and presented by: IZIDORE LOSSOS, MD
Program curriculum developed and presented by: IZIDORE LOSSOS, MD Professor of Medicine, University of Miami Director, Lymphoma Program Sylvester Comprehensive Cancer Center, Miami, FL SONALI M. SMITH,
More informationIl trattamento del Linfoma Follicolare in prima linea
Il trattamento del Linfoma Follicolare in prima linea Dr.ssa Carola Boccomini SC Ematologia Dr. U. Vitolo AO Città della Salute e della Scienza Torino, Italy Median follow-up 3 years Median follow-up 6
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology December 2013 Integrating Emerging Treatment Options in Mantle Cell Lymphoma Moderator Discussants Brad S. Kahl, MD Skoronski Chair
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma. Reference: NHS England 1630
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma Reference: NHS England 1630 1 First published: TBC Prepared by NHS England Specialised
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More information1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationFrontline therapy and role of high-dose consolidation in mantle cell lymphoma
MANTLE CELL LYMPHOMA Frontline therapy and role of high-dose consolidation in mantle cell lymphoma Simon Rule Department of Haematology, Derriford Hospital, Plymouth and Plymouth University Peninsula Schools
More informationPatient Case Studies & Panel Discussion
Patient Case Studies & Panel Discussion Panelists: Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center; Ranjana H. Advani, MD, Stanford Cancer Institute; Andrew D. Zelenetz, MD, PhD, Memorial
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationMantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management
Received: 18 May 2017 Accepted: 18 May 2017 DOI: 10.1002/ajh.24797 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES: A CONTINUING MEDICAL EDUCATION SERIES Mantle cell lymphoma: 2017 update on diagnosis,
More informationMantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care? Authors: *Susmita Sharma, 1 John W. Sweetenham 2 1. Department of Hematology/Oncology, Huntsman Cancer Institute, University of Utah,
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationClinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages)
Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: 170029P 1 NHS England INFORMATION READER BOX Directorate Medical
More informationRecent Advances in the Treatment of Non-Hodgkin s Lymphomas
671 Highlights of the NCCN 18th Annual Conference Recent Advances in the Treatment of Presented by Jeremy S. Abramson, MD, and Andrew D. Zelenetz, MD, PhD Abstract Non-Hodgkin s lymphomas (NHL) represent
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationNew developments in the treatment of FL. Massimo Federico University of Modena and Reggio Emilia Italy
New developments in the treatment of FL Massimo Federico University of Modena and Reggio Emilia Italy Common Questions Asked by The Patient I would like to know what is the best therapeutic option and
More informationNotification to Implement Issued by pcodr: December 14, 2012
PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further
More informationDiffuse Aggressive Lymphoma
Diffuse Aggressive Lymphoma Richard I. Fisher, Thomas P. Miller, and Owen A. O Connor The aggressive non-hodgkin s lymphomas can be cured in more than half of the cases. However, there has been great variation
More informationBackground. Outcomes in refractory large B-cell lymphoma with traditional standard of care are extremely poor 1
2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Abstract 2967 Neelapu SS, Ghobadi A, Jacobson
More informationClinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: P
Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: 170054P 1 NHS England INFORMATION READER BOX Directorate Medical
More informationAre we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma?
Mantle cell lymphoma has been recognized as a distinct entity from the other non-hodgkin lymphomas in middle 1990 s. It carries a worst prognosis among all mature B-cell malignancies. Cyclin D1 and recently
More informationClinical Commissioning Policy: Bendamustine with rituximab for first line treatment of mantle cell lymphoma (all ages)
Clinical Commissioning Policy: Bendamustine with rituximab for first line treatment of mantle cell lymphoma (all ages) NHS England Reference: 17088P NHS England INFORMATION READER BOX Directorate Medical
More information